To avoid complications, Zsolt szabó, MD, PhD, of Miskolc, Hungary, urged surgeons to be familiar with injectable collagenase clostridium histolyticum before using it in patients with Dupuytren’s contracture.
Injectable collagenase clostridium histolyticum has revolutionized treatment for Dupuytren’s contracture. In many cases, for the first time clinicians can treat these finger contractures without surgery using a drug that has few complications. But since its introduction in Europe in 2011, some orthopaedists have worried whether the new treatment would completely replace hand surgery as a treatment for Dupuytren’s contracture, according to investigators who treat patients with this disease.
Read the full article in the July/August 2013 issue of the EFORT OTE newsletter
